Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study

•After 36 weeks there were no differences in response to PCSK9-I therapy between FH subgroups according to genotype.•Response to PCSK9-I was significantly lower in carriers of compound-He/Ho mutations.•Target achievement rate still represents an issue in FH patients despite high efficacy of available lipid lowering therapy.